ADMA Biologics Inc. (NASDAQ:ADMA) shares are down on Wednesday following a report from Culper Research that raised concerns about the company's financial practices.

• ADMA Biologics stock is testing key support levels. What’s pressuring ADMA?

Culper Research Describes ADMA Short; Alleges Misreporting

The report from Culper Research, released on Tuesday, alleges that ADMA Biologics has been misrepresenting its financial results and operating metrics.

The firm disclosed that it holds a short position in ADMA, which adds a layer of skepticism to its claims.

In response, ADMA Biologics emphasized its commitment to transparency and adherence to U.S. Securities and Exchange Commission regulations, stating that the assertions made in the report are based on unreliable sources.

The company is reviewing the claims made by Culper Research and reaffirms its dedication to maintaining accurate public disclosures.

ADMA Biologics reported adjusted earnings of 21 cents per share, beating the consensus of 18 cents. Sales reached $139.16 million, missing the consensus of $139.40 million.

The company forecasts fiscal 2026 revenue of more than $635 million versus the consensus of $633.75 million, and fiscal 2027 sales of over $775 million compared to the consensus of vs $771.8 million.

ADMA 28.2% Below 20-Day SMA

ADMA Biologics is currently trading 28.2% below its 20-day simple moving average (SMA) and 35.4% below its 100-day SMA, indicating significant weakness in its short-term trend.

Shares have decreased 45.70% over the past 12 months and are positioned closer to their 52-week lows than highs, reflecting a challenging year for the stock.

The RSI is at 23.87, which is considered oversold territory, suggesting potential for a rebound if buying interest returns. Meanwhile, the MACD is at -0.7757, below its signal line at -0.4535, indicating bearish momentum in the stock.

The combination of oversold RSI and bearish MACD suggests mixed momentum, highlighting the need for cautious trading strategies in the current environment.

  • Key Resistance: $15
  • Key Support: $10.90

ADMA Biologics Edge: Value 49.42, Momentum 13.76

Below is the Benzinga Edge scorecard for ADMA Biologics, highlighting its strengths and weaknesses compared to the broader market:

  • Value: 49.42 — The stock is trading at a fair valuation relative to peers.
  • Momentum: 13.76 — Stock is underperforming the broader market.

The Verdict: ADMA Biologics’ Benzinga Edge signal reveals a weak profile, with significant concerns regarding its momentum and value positioning in the current market landscape.

ADMA Stock Price Activity: ADMA Biologics shares were down 13.15% at $9.84 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock